Several prognostic and predictive factors influence the clinical course of MBC including factors reflecting the tumour biology, such as hormone-receptor (HR) status and human epidermal growth factor receptor 2 (HER2) status, but also age, performance status, and the location and number of distant metastases [12, 13]. Here, ERBB2 is linked to neoplasm.